Lisanti Capital Growth LLC boosted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 100.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 100,245 shares of the company’s stock after acquiring an additional 50,265 shares during the period. Lisanti Capital […]